Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-006 Safari study

Kawaguchi, Hidetoshi ¹Yamamoto, Yutaka ²Saji, Shigehira ³Masuda, Norikazu ⁴Nakayama, Takahiro ⁵Aogi, Kenjiro ⁶Anan, Keisei ⁷Ito, Yoshinori ⁸Ohtani, Shoichiro ⁹Sato, Nobuaki ¹⁰Takano, Toshimi ⁸Tokunaga, Eriko ¹¹Nakamura, Seigo ¹²Hasegawa, Yoshie ¹³Hattori, Masaya ¹⁴Fujisawa, Tomomi ¹⁵Morita, Satoshi ¹⁶Yamaguchi, Miki ¹⁷Yamashita, Hiroko ¹⁸Yamashita, Toshinari ¹⁹Yotsumoto, Daisuke ²⁰Toi, Masakazu ¹⁶Ohno, Shinji²¹

扫码查看

作者信息

1. Dept Breast Surg,Matsuyama Red Cross Hosp
2. Dept Breast & Endocrine Surg,Kumamoto Univ
3. Dept Med Oncol,Fukushima Med Univ
4. Natl Hosp Org,Osaka Natl Hosp
5. Dept Breast & Endocrine Surg,Osaka Int Canc Inst
6. Dept Breast Oncol,NHO Shikoku Canc Ctr
7. Dept Surg,Kitakyushu Municipal Med Ctr
8. Dept Breast Med Oncol,Canc Inst Hosp JFCR
9. Dept Breast Surg,Hiroshima City Hiroshima Citizens Hosp
10. Dept Breast Oncol,Niigata Canc Ctr Hosp
11. Dept Breast Oncol,Kyushu Canc Ctr
12. Dept Surg,Showa Univ
13. Dept Breast Surg,Hirosaki Municipal Hosp
14. Dept Breast Oncol,Aichi Canc Ctr Hosp
15. Dept Breast Oncol,Gunma Prefectural Canc Ctr
16. Grad Sch Med,Kyoto Univ
17. Dept Breast Surg,JCHO Kurume Gen Hosp
18. Dept Breast Surg,Hokkaido Univ Hosp
19. Dept Breast & Endocrine Surg,Kanagawa Canc Ctr
20. Dept Breast Surg Oncol,Miyazaki Hakuaikai Med Corp
21. Breast Oncol Ctr,Canc Inst Hosp JFCR
折叠

Abstract

Background: The Safari study (UMIN000015168) was a retrospective, multicenter study in which 1072 consecutive cases of estrogen receptor-positive advanced breast cancer treated using 500 mg fulvestrant were registered. We previously reported the relationship between the patient factors and overall survival after the diagnosis using the same cases and the same factors for the analysis of time to treatment failure in patients with estrogen receptor-positive advanced breast cancer. The current study is an ad hoc analysis that focused on the relationship between the patient factors and overall survival after recurrence by adding factors generally associated with overall survival after recurrence. Methods: The overall survival after recurrence in patients with estrogen receptor-positive human epidermal growth factor receptor 2 negative recurrent breast cancer was analyzed via univariate and multivariate analyses with a Cox proportional hazards model. Results: A total of 598 cases were used for the analysis of overall survival after recurrence. Multivariate analysis revealed that favorable overall survival (median, 6.4 years) was significantly correlated with long time from recurrence to fulvestrant use (>= 3 years), low nuclear or histological grade (G3 vs. G1), long time to treatment failure of initial palliative endocrine therapy (>= 12 months) and long time to initial palliative chemotherapy (>= 2 years). Conclusion: The results of this study indicate that sequential endocrine monotherapy may be a useful treatment option for patients with estrogen receptor-positive/human epidermal growth factor receptor 2 negative recurrent breast cancer who have been successfully treated with initial long-term palliative endocrine therapy.

Key words

breast cancer/antineoplastic agents/post-menopause/hormones/overall survival/DORMANCY/WOMEN

引用本文复制引用

出版年

2022

Japanese journal of clinical oncology.

ISSN：0368-2811

被引量1

参考文献量33

段落导航